HomeREGULATORY
REGULATORY

Xofluza Subject to April Price Revision, but Will Maintain Full Price: MHLW Official
(Mar.8.2018)

Shionogi’s single-dose influenza drug Xofluza (baloxavir marboxil), which was approved for accelerated listing on March 14, will be included in the scope of listed drugs going through the upcoming price revision next month, but its NHI price will remain unchanged, according to a health ministry official ...
(LOG IN FOR FULL STORY)

News Calendar